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Abstract
Background: Epilepsy, multiple sclerosis (MS), and depression are chronic conditions where technology holds potential in
clinical monitoring and self-management. Over 5 years, the Remote Assessment of Disease and Relapse - Central Nervous System
(RADAR-CNS) consortium has explored the application of remote measurement technology (RMT) to the management and
self-management of patients in these clinical areas. The consortium is large and includes clinical and nonclinical researchers as
well as a patient advisory board.
Objective: This formative development study aimed to understand how consortium members viewed the potential of RMT in
epilepsy, MS, and depression.
Methods: In this qualitative survey study, we developed a methodological tool, universal points of care (UPOC), to gather
views on the potential use, acceptance, and value of a novel RMT platform across 3 chronic conditions (MS, epilepsy, and
depression). UPOC builds upon use case scenario methodology, using expert elicitation and analysis of care pathways to develop
scenarios applicable across multiple conditions. After developing scenarios, we elicited views on the potential of RMT in these
different scenarios through a survey administered to 28 subject matter experts, consisting of 16 health care practitioners; 5 health
care services researchers; and 7 people with lived experience of MS, epilepsy, or depression. Survey results were analyzed
thematically and using an existing framework of factors describing links between design and context.
Results: The survey elicited potential beneficial applications of the RADAR-CNS RMT system as well as patient, clinical, and
nonclinical requirements of RMT across the 3 conditions of interest. Potential applications included recognition of early warning
signs of relapse from subclinical signals for MS, seizure precipitant signals for epilepsy, and behavior change in depression. RMT
was also thought to have the potential to overcome the problem of underreporting, which is especially problematic in epilepsy,
and to allow the capture of secondary symptoms that are not generally collected in MS, such as mood.
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Conclusions: Respondents suggested novel and unanticipated uses of RMT, including the use of RMT to detect emerging side
effects of treatment, enable behavior change for sleep regulation and activity, and offer a way to include family and other carers
in a care network, which could assist with goal setting. These suggestions, together with others from this and related work, will
inform the development of the system for its eventual application in research and clinical practice. The UPOC methodology was
effective in directing respondents to consider the value of health care technologies in condition-specific experiences of everyday
life and working practice.
(JMIR Form Res 2020;4(11):e22756) doi: 10.2196/22756
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Prior work has recognized the need for health information
technologies (HITs) to consider socio-technical facets used over
time and the varying trajectories experienced within and between
health care services [1]. Previous work in mobile health has
indicated how technologies may be able to alter the relationship
and dynamics of clinician-patient interactions, where previously
the clinician has been seen as the main decision maker and
expert provider of information and knowledge [2,3]. The
introduction of monitoring, measurement, and communication
technologies should, in principle, support informed
patient-clinician partnerships and greater shared decision
making, although there may be barriers to their use [4,5].
The importance of ensuring that the requirements of all users
are considered early in the design process of products and
services is well established. The benefits of user-centered design
approaches underpin improved usability and adoption, and
human factors and ergonomics is a key discipline in this area
[6]. In particular, through a systems approach to design, the
added value of novel technologies can be understood when these
advances enable new ways of working, speed up or make
existing practices easier, or enhance the user experience [7]. In
addition, this perspective supports the inclusion of all users
within a system and aims to understand the multiple
socio-technical interactions of a new intervention, whether they
are human-to-human interactions, human-to-technology
interactions, or any permutation. Despite this knowledge and a
regulatory landscape supporting the inclusion of all stakeholders
during design and development, there is evidence that HITs
producers are still responding to technology push, and the
requirements of all users are not necessarily prioritized during
system development [8].
In this study, we aim to investigate how the introduction of a
remote measurement technology (RMT) platform might alter
current practices in care pathways for people with epilepsy,
multiple sclerosis (MS), or depression and identify where, how,
and why clinicians and patients may derive value from the RMT
platform once in practice.
Study Technology Overview
The Remote Assessment of Disease and Relapse - Central
Nervous System (RADAR-CNS) RMT platform under
consideration in this study is being designed for use in the
clinical management and patient self-management of 3 long-term
conditions: epilepsy, MS, and depression. However, the
long-term goal is for a flexible, ubiquitous platform that can be
adapted to support the management of a wide range of
conditions spanning physical and mental health domains as well
as use in research.
The RMT system in development consists of wearables and
mobile phone apps run on consumer mobile devices. A passive
remote measurement technology software component processes
sensor data such as activity and location. Passive data collection
systems have been used in various applications in general health
[9] and mental health in particular [10]. An active remote
measurement technology component processes user-supplied
data entries. This includes data from short questionnaires
completed at regular intervals on mobile devices after
notification to the user, usually termed ecological momentary
assessment or experience sampling method, and other prompted
input such as voice samples. Longitudinal data sets are collected
from individual users with the aim of processing through
predictive algorithms to understand whether early detection and
warning of relapse and/or disease change (worsening or
improvement) can be identified via RMT.
Furthermore, a number of translational work packages exist to
probe the user acceptability and fit of RMT to health care
systems and in the everyday lives of health care professionals
and patients. All work is at a formative stage, and no system
has been introduced into health care practice at this stage. In
the initial iteration of the system, which is used in observational
research studies, there is no predictive element and no feedback
from the system to the patient, although these are features that
have the potential to be developed and included in the longer
term. Figure 1 illustrates how use in research and practice will
inform further development of the platform.
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Figure 1. Diagram showing how the platform under development is intended for use in clinical practice and research. The platform is supplied with
data from passive and active remote measurement technology worn or carried by patient users, as instructed by the clinic or in research protocols. Use
in research and practice will inform further development of the platform. RMT: remote measurement technology.
Scenario-Based Design
Use cases and design scenarios have been used in design
processes since the early 1990s [11] and constitute a key tool
when exploring technology users’ needs and the nature and
requirements of cooperative work systems [12,13]. Within the
field of health care, use case scenarios have been applied in
investigations into clinical decision making and associated tools
and aids [14-16] and in further understanding knowledge sharing
in distributed working practices [17]. Scenarios help participants
to envisage how new technologies might be implemented in
practice where these are not yet common. Scenarios are useful
because they encourage consideration of multiple facets of a
situation and foster elicitation of views that can inform the
development of tools and services. However, use case scenarios
tend to work best in task-specific contexts, where parameters
are clearly defined and the outcome of use is predictable [18].
Conversely, digital health care systems tend to be complex in
nature, with multiple users, addressing multiple medical
conditions, and with unpredictability in use [19]. In this paper,
we describe the use of a new methodology, based on use case
scenarios, to inform the design of the RADAR-CNS RMT
system, which is to be used in research and ultimately in clinical
practice. The system is required to work across multiple
conditions, collecting data from patients who have differing
requirements from health care professionals treating them. Thus,
we required a methodology to inform the design of the system
to ensure applicability within and between conditions. The
methodology was also required to allow participants in the
research program (clinicians and patients) to contribute from
their own expertise and experience, without having to adapt the
research method for each condition. We call our approach
universal points of care (UPOC).
Methods
Approach
A survey was developed to elicit opinions from European health
care professionals and researchers within the consortium and
the patient advisory board (PAB), which was made up of
individuals with lived experience of the 3 conditions of interest.
The aim was to focus on the potential and practicalities of RMT
use in everyday practice. In particular, we sought to carry out
a preliminary investigation into the current practices across the
3 central nervous system (CNS) conditions. The intention was
to provide space for clinical opinion to explore prospectively
how practice would (or could) be affected by the introduction
of the RADAR-CNS RMT system and to uncover needs and
concerns about this. The approach taken was to ask participants
about a series of preidentified points of care common across
the 3 conditions, and then to elicit further points of care that
may be affected by the introduction of the RMT system. Generic
clinical scenarios were identified through expert elicitation and
exploration of clinical pathways. The developed scenarios
became UPOC exemplars, providing the basis for an inquiry
that would be relevant to multiple clinical conditions.
Development of UPOC Exemplars
Clinical pathways provide a framework through which changes
relevant to the implementation of new technologies and devices
can be considered. Clinical pathways represent care management
within a clinic setting [20] and can also refer to the planned,
managed delivery of care over time and by care teams in a range
of clinical settings, as per the definition of clinical pathways
provided by the European Pathway Association [21].
JMIR Form Res 2020 | vol. 4 | iss. 11 | e22756 | p. 3http://formative.jmir.org/2020/11/e22756/
(page number not for citation purposes)
Craven et alJMIR FORMATIVE RESEARCH
XSL•FO
RenderX
The UPOC were informed by consultation of academic and gray
literature on clinical pathways in each of the following
conditions: a review of treatment pathways for MS [22], an
international audit of epilepsy services worldwide [23], and the
European Psychiatric Association’s guidance on psychotherapy
in chronic depression [24], among other work. The UPOC were
derived by reviewing existing clinical pathways and decision
points of the 3 target clinical areas via examination of the
National Institute for Health and Care Excellence care pathway
maps [25]. These maps consist of interactive flowcharts
presenting details of the recommendations for managing patients
of different groups (eg, by age), including the recommended
steps involved in diagnosis and treatment. Here, we focused on
the pathways for epilepsy, MS, and depression. Knowledge was
also gained from informal discussions with clinicians in the
consortium, focusing on personal experiences of care provision
and reflecting on the current clinical pathways for epilepsy, MS,
and depression.
Once identified, the UPOC were designed into the survey, and
participants were asked to consider how those UPOC might be
experienced both without and with an RMT system in place, to
contrast current care provision with future care provision when
the RADAR-CNS RMT system is deployed. It was decided that
participants would also be invited to describe any additional
use scenarios that they believed would be encountered in care
delivery or receipt with the use of RMT.
Participants
A convenience sampling method was used to recruit members
of the consortium to take part in the survey, some at an annual
meeting that took place in April 2018 and some shortly after.
To encourage engagement, a panel session was held at the
annual meeting, with presentations by 3 clinicians and 3
members of the PAB discussing value propositions of novel
health care technologies. This also included details on the
content, aims, and importance of the survey. Delegates of the
meeting were asked to complete the survey immediately
afterward. Members of the consortium were freely able to take
part (or not). The survey was administered via a web-based
interface for ease of access and to provide the opportunity for
remote completion. PAB participants were given the option to
complete the survey by hand, by email, or by phone—in the
latter case, a researcher made hand-written notes on a printed
survey form for each survey administered. Due to their
involvement in the research program, all the participants had
baseline knowledge of the RADAR-CNS RMT system and its
potential functional capabilities, for example, remote monitoring
of disease, distributed and computer-supported delivery, and
receipt of care and personalized medicine. Participants were
asked to respond in relation to the condition on which they had
most knowledge.
Survey Sections
The survey was divided into 6 sections, A-F, as follows. All
respondents were encouraged to answer all questions. The
survey instrument is available in Multimedia Appendix 1. An
overview of survey sections is provided in Table 1. These are
shortened titles of the survey sections; more comprehensive
titles were used in the survey itself, and they can be found in
Multimedia Appendix 1.
Table 1. Survey sections.
Survey sectionsSections
Respondent informationSection A
Promise of RMTaSection B
UPOCb 1-6 comparing existing and future potential careSection C
Respondent-provided UPOCSection D
Use of RMT dataSection E
Reflections and commentsSection F
aRMT: remote measurement technology.
bUPOC: universal points of care.
Section A of the survey collected demographic information
about the respondents, including names; geographical location;
role in the partnership; and where relevant, place of work,
clinical or research specialty, and for the PAB respondents, their
clinical condition.
Section B was designed to gather general opinion about the
promise of RMT.
Section C presented the UPOC to participants for them to
consider how these occurred in their experience before
RADAR-CNS and how they may occur after RADAR-CNS.
Questions in the survey text prompted consideration of various
aspects of the UPOC: Where does the interaction take place?
Are any communications in real time or is there a delay? What
are the positives about this way of interacting? What are the
negatives about this way of interacting? Six UPOC that were
identified and used in the survey are presented in Textbox 1.
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Textbox 1. The 6 universal points of care for which the respondents were asked to provide details about the scenarios before and after the introduction
of remote measurement technology.
Patient sharing data with clinician
• A patient has been monitoring how they feel (activity, mood, sleep, etc) for 2 weeks. They have some concerns and would like to share their data
with their clinician. How might this happen?
Relapse detection (symptomatic)
• A patient is not feeling well and might be on the path to relapse. How do you (patient or clinician) try to understand if a relapse is imminent or
occurring?
Relapse detection communication (recently diagnosed patient)
• The patient might be headed for a relapse. The clinician and the patient have not been working together for very long, and the patient is still
getting used to their diagnosis. How would this be communicated?
Relapse detection communication (patient diagnosed for a long time)
• The patient might be headed for a relapse. The clinician and the patient know each other well, and the patient has been living with the condition
for a long time. How would this be communicated?
Medication selection or dosing (recently diagnosed patient)
• The patient’s medication needs modification. What is the best way of informing them of this decision and providing them with information?
Medication selection/dosing (patient diagnosed for a long time)
• The patient’s medication needs modification. What is the best way of informing them of this decision and providing them with information?
In section D, respondents were asked to offer up to 2 additional
UPOC of their own, inviting them to consider “other situations
where use of the technology might change your decisions,
behaviours or experiences or the way in which you interact with
other people (clinicians, patients, other healthcare
professionals).” In section E, respondents were asked to consider
the possibility of 2 more speculative UPOC specific to RMT
implementation: (1) stratification of patient risk for relapse and
(2) dealing with different patient responses to treatment. During
analysis, these were then rated as either considered useful,
considered possible, would need more research, or have
concerns. In section F, any final additional comments were
collected.
Data Analysis
Data were gathered via a web-based interface, Bristol Online
Surveys [26], which collected and grouped the raw data of
respondents for section A-F of the survey. The raw data
consisted of single sentences or short paragraphs written by
individual respondents to each question that was posed.
Thematic analysis [27] was carried out on the collected data.
Responses were coded by 2 coders in 2 iterations, whereby each
individual response (or excerpt from a paragraph) was given a
descriptive term to create a set of initial themes for each section
of the survey (refer to the Results section for examples of these
terms). The responses or excerpts coded with the initial themes
were cut and pasted into tables that were reviewed and combined
into a smaller set of final themes for that section. During the
transfer to tables, data from the different clinical specialties
were color coded to help identify condition-specific patterns.
In the presentation of the final thematic coding structure, this
approach enabled analysis within and between conditions. Data
from the PAB were themed separately by a third coder in a
single iteration after analysis of the results. The coding was
based on the themes found in the web-based survey, with the
intention to draw out commonalities and differences from the
health care professionals.
Responses within the final themes were analyzed further to
qualify the benefits participants saw to the introduction of RMT,
using the following framework of descriptors adapted from
Sharples et al [7]:
• Enabler: The introduction of the device/system permits a
new process or function to be possible (ie, it is not currently
possible).
• Enhancer: The introduction of the device/system permits
an improved outcome (ie, it has an impact on effectiveness).
• Facilitator: The introduction of the device/system makes a
process or function easier (ie, it has an impact on
satisfaction and adherence).
• Catalyst: The introduction of the device/system speeds up
a process or function (ie, it has an impact on efficiency).
Results
Overview
The surveys returned were generally well completed. No
portions of the survey were consistently ignored, although in
response to some questions, participants signposted to earlier
responses given, indicating that the answer was applicable to
multiple UPOC. Furthermore, not all respondents provided their
own suggested use cases in section D.
Section A: Respondent Information
Table 2 shows number of respondents to the survey from
different roles within the consortium. As the health care system
was the main focus of the work package, survey responses from
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translational, technical, and clinical respondents were analyzed
separately from responses provided by the 7 members of the
PAB, results for which are presented at the end of this section.
Table 2. Respondent roles in the consortium.
Participants (n=28), n (%)Role in research program
Translational
3 (11)Health service researchers (clinical pathways, patient and public involvement, regulatory requirements)
Technical










Section B: Promise of RMT
Table 3 shows a summary of the 9 final themes arising from
section B. Further details on the contents of each theme are
available in Multimedia Appendix 2. Responses to the section
on the promise of RMT (potential uses) were analyzed
thematically, where 15 initial descriptive terms were attached
to the qualitative data and were merged to form a shorter list of
9 final themes, which are listed in Table 2. The themes were
generally aligned to the purposes of the study and revealed
aspects that were clinician focused as well as reflecting on
patient behaviors and experiences. The themes also revealed
opportunities for use of the platform, for example, roles in
clinical trial design and clinical decision making as well as
raising concerns for their use.












bNot present in transcript.
We assigned relevant qualifiers to responses under each theme
(enabler, enhancer, catalyst, and facilitator, as described above).
For example, under the theme of clinical verification,
participants suggested that the RADAR system could enable
the measurement of deterioration of motor system in progressive
MS. Under monitoring potential, respondents indicated that the
system could enhance patient management through faster and
more detailed ecological assessment of emotional and physical
state. In relation to research, respondents suggested that data
collected using the RADAR system could be used to detail the
characterization of the progression of MS and that this could
enable new designs of clinical trials.
The results demonstrate that participants largely viewed RMT
as enabling new processes or functions that were not currently
possible. Fewer responses described ways that RMT would
enhance or facilitate care provision, and only one provided an
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example of how RMT could speed up, or catalyze, existing
processes (Table 3).
One theme, device issues, did not fit with the classification of
these qualifiers; however, it was considered important to include
this in the analysis, as this theme captured some of the practical
challenges associated with use of these devices, for example,
the accuracy of activity trackers. Device issues have been
explored in further detail elsewhere in the consortium [28,29].
Section C: UPOC 1-6 Comparing Existing and Future
Potential Care
The findings from section C, consisting of comparisons between
existing care and potential care with the RADAR-CNS RMT
system in different UPOC scenarios, are summarized below.
UPOC 1: Patient Sharing Data With Clinician
Respondents described that currently, information from patients
is conveyed at face-to-face appointments or by phone but that
RMT could permit transfer of data to a patient health
information system before an appointment, permitting the
automatic creation of a report. Clinician respondents suggested
that this could be done over an encrypted channel to ensure data
security.
Survey responses also indicated that the conventional means
for aggregating data was via a manual patient diary; however,
it was thought that the RADAR-CNS RMT system could
summarize data automatically. The patient may have access and
filter the data for relevance beforehand. In terms of clinical
utility, RMT might replace or supplement conventional measures
made in the clinic (eg, disability measures in MS), with the
added advantage in epilepsy to overcome underreporting of
seizures and thereby better inform medication adjustments.
In terms of timing, RMT permits data submission (by patients)
and data analysis (by clinicians) at convenient times. However,
concerning workload, respondents noted the potential for added
burden to the clinician or, more generally, the health care
provider organization, outside of appointment times.
UPOC 2-4: Relapse
Clinicians expected that the RADAR system would allow them
to see if a relapse occurs; however, there was concern about
both sensitivity and specificity, for example, that the relapse
signal might be a false positive arising from another illness like
influenza or that a true relapse may be missed (offering false
reassurance). In terms of immediacy, respondents mentioned a
delay in consultation without RMT either to a clinic appointment
or a phone call from the clinician, whereas with the system, the
emergency clinical service could receive an automatic alert (for
depression relapse) or else prompt a clinician contact if an early
sign of relapse had occurred (MS), employing a digital
dashboard for the clinical team to manage this for all their
patients.
It was considered that RMT could afford the opportunity to start
an immediate intervention via a smartphone or else afford an
earlier intervention than was possible without it. In terms of
health care system benefits, there was a concern that data from
RMT could overload or overburden the system; however, it
could also benefit the health care system by reducing routine
clinic visits for patients who are well and substitute routine
visits by information provided remotely using RMT.
For a patient with a recent diagnosis having symptoms of relapse
(UPOC 3), respondents described that the conventional approach
was to see the patient in clinic, and this would be essentially
unchanged with RMT, except for the potential for more
continuous monitoring, resulting in a blended solution. As
mentioned above, the main method for interaction with RMT
would be via a clinician or team dashboard. For a very new
depression diagnosis, RMT could be used to provide patients
with access to information about their condition. For epilepsy,
the system would detect closely spaced seizures or physiological
markers indicating imminent relapse. For MS, it was also judged
that it would take time to understand the symptoms in context
from the RMT data, for example, variation due to the weather.
For a patient with a longer-term diagnosis having symptoms of
a relapse (UPOC 4), the picture was similar to the above, but
because a patient’s relapse pattern would more likely be known,
the additional RMT data might prompt a change in the treatment
plan. There was an additional general concern (not specific to
RMT) that communication with the patient about a new
depressive episode could increase the likelihood of depressive
symptoms.
In general, longer-term data should enable more remote
consultation, for example, by a phone call rather than a clinic
visit, and a faster response.
UPOC 5 and 6: Medication Management
This section of the survey asked respondents to consider
medication management before and after the imagined
implementation of the RADAR-CNS RMT system, first in a
new diagnosis of a CNS condition (UPOC 5) and second when
a patient had lived with a condition for a long time (UPOC 6),
with a view to examining differences in practice or perception.
The results showed little difference between these 2 phases of
conditions; thus, the results have been presented together.
The added benefit of RMT for newly diagnosed patients was
considered to be low, as medication reviews would still need
to happen face to face. Without RMT, people with epilepsy
would write their own notes and wait for a change to a drug
prescription, whereas with RMT, this could be done more
efficiently via a mobile app. For depression, behavioral or social
problems were considered difficult to detect remotely, although
clinical information sent by the patient via RMT was envisaged
as a way to trigger scheduling of an appointment. For MS, it
was considered that the system might replace clinical scoring
and magnetic resonance imaging, and fluctuations in disease
activity might prompt a change in therapy. For a longer-term
patient (UPOC 6), the results were mostly the same as those for
UPOC 5, but one clinical respondent thought a change in
treatment for a longer-term MS patient might be enacted via a
phone call and the platform used to monitor the effect, rather
than face to face (which they would recommend for a new
patient).
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Respondents were asked about the use of RMT data in clinical
practice in general and were then asked about patient
stratification and treatment response as 2 areas of interest. Areas
of use of RMT data included improvement of clinical decision
making and the enabling of more personalized care. RMT would
be used to identify individual baselines or norms and individual
patterns of behavior. It could also help discover population-level
risk factors in MS and epilepsy, although it might not be as
useful in the latter due to greater variation between individuals.
For depression, RMT data could help educate the patient even
if it were not possible to identify relapse signatures for
individuals. It was considered, by a technical team respondent,
that anomaly detection algorithms used in finance and industry
could be used for RMT data to detect both individual- and
population-level patterns. More research is needed, including
the results of observational clinical studies, to determine whether
RMT could be employed in therapeutic trials and to confirm
whether it has a positive impact on individual disease
management and patient outcomes.
Focusing on stratifying patients by risk or clustering in general,
there were differences between specialties. In epilepsy, one
example was dividing patients with more hazardous, frequent
convulsive seizures from those with frequent focal seizures. For
MS, RMT could allow clinicians to confirm a set of risk factors
in the general MS population and determine how many of those
risk factors are present for an individual patient. For depression,
it was considered that RMT data could be used to test different
treatments (on different groups) and potentially to stratify by
genetic risk. It was considered that more research would be
required to see how much data are needed to discover population
risk factors and to determine if the population data are
informative at the patient level for individual management.
PAB
A total of 7 members of the PAB completed the survey as
potential users of the system and provided a range of views on
the benefits of RMT, mentioned personal areas of interest for
using the technology, and raised some concerns. These 7
members included 2 members with experience living with
depression, 2 members with epilepsy, and 3 members with MS.
Like clinicians, patients emphasized the importance of
collaborative decision making about medication and highlighted
across all 3 conditions the need to maintain face-to-face
appointments even with the introduction of new technologies.
However, with an RMT system in place, patients saw potential
in having clinicians view their records between appointments,
allowing side effects to be detected early on, and medication
changes to be instigated earlier.
Patients also gave specific examples of signals that might be of
interest, such as spelling mistakes and typing speed on mobile
phones in MS. These points were not raised by health care
professionals. There was also interest in considering potential
negative effects arising from RMT use. For example, people
with MS highlighted that they may not want to be informed by
RMT that their condition was deteriorating, and people with
depression mentioned that they prefer not to think about their
condition between their 6-monthly clinical appointments.
Patients explained that they currently relied to a high degree on
verbal communication with clinicians and their own memories
of what had occurred between appointments. They
acknowledged that these memories may not always be accurate,
particularly in the case of epilepsy where some seizures may
go undetected, and that the use of the system could provide
more accurate data to base clinical decisions on. On the other
hand, they also suggested that there may be a risk of increased
anxiety due to tracking.
Discussion
Formative Development of the System via UPOC
Methodology
From a methodological perspective, UPOC have been effective
in eliciting condition-specific descriptions of current and
potential processes from clinicians and patients. Figure 2
illustrates the coverage of the UPOC methodology across
conditions and stakeholder requirements. Although the survey
form provided was identical in all cases, participants were able
to describe aspects of care within their relevant condition with
details on their particular context, providing a rich set of data
to support analysis of need, opportunity, and concern within
and between conditions. For example, it was suggested that
RMT should enable recognition of early warning signs of
relapse, including identifying subclinical signals for MS, seizure
precipitant signals for epilepsy, and behavior change in people
living with depression. In terms of clinical utility, it was
considered that RMT might overcome the problem of
underreporting, which is especially problematic in epilepsy. It
was also thought that RMT may allow the capture of secondary
symptoms that are not generally collected in MS, such as mood.
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Figure 2. Diagram showing the coverage of the universal points of care methodology in the development of a novel remote measurement technology
system. MS: multiple sclerosis; RMT: remote measurement technology.
Several novel and unanticipated uses of RMT were suggested
by respondents. For depression, it was considered that RMT
could help extend investigations into psychotherapies and digital
mental health interventions. For epilepsy, active remote
measurement technology with questionnaires could also be used
to detect emerging side effects of treatment, although care would
need to be taken to understand the responses correctly before
acting. It was considered that RMT could enable behavior
change for sleep regulation and activity and that it could be
helpful in detecting minor relapses for people with cognitive
impairments who may not mention them in the clinic and thus
help prompt or guide escalation of care. RMT was also
considered to offer a way to include family and other carers in
a care network, which could assist with goal setting, although
with care to avoid the risk of overreliance on information from
carers, which may not be reliable. Although the current iteration
of the system was not designed to feed data or analyses from
the system to the patient, this is an aspect of usage that could
be added to future iterations to facilitate the operations described
here.
The novel adaptation of a medical device usability model [7]
with its 4 embedded qualifiers (enabler, enhancer, facilitator,
or catalyst) helps developers understand more precisely how
patients perceive value in the system being designed. In this
study, the method was used to structure the results of the end
user inquiry. The method could also be used in summative
evaluation to test whether the promise of improvement is
realized at key stages of an iterative design process.
Comparison With Related Work
This study included patients and research clinicians to contribute
a multistakeholder perspective considering where and how RMT
might improve care in 3 conditions, which has been described
as lacking in a review of the literature in this area [9]. In
particular, this study has added to the existing work by
demonstrating how clinicians and patients view the promise of
RMT as a way of altering clinician-patient interactions.
Previously, the clinician has been seen as the main decision
maker and expert provider of information and knowledge in the
clinician-patient relationship [2,3]. Both parties envisaged ways
that patients could act as custodians of their own data (eg, by
being able to access and manage it) but they also emphasized
that enabling the remote transmission of data should not result
in the removal of all face-to-face interactions, a finding that is
supported by other work in this area [30].
The consortium has also explored wider patient views of RMT
in the 3 conditions [5,31,32]. Although these studies focused
on the barriers and facilitators of the use of RMT, this study
involved members of the PAB who had significant knowledge
of the project, enabling the collection of their ideas on particular
features in the data collected from the RMT that could be used
for monitoring the deterioration of their own condition. For
example, PAB members made the observation that in MS,
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spelling mistakes and typing speed on mobile phones may be
of use in detecting changes in their cognitive state. There was
also interest in detecting early side effects of medications,
permitting the earlier change of medication where this was
problematic. Thus, patients themselves were empowered in this
study to speak from their own insight and suggest how RMT
could be serviceable to them both in detecting changes in their
condition and managing potential for harm.
In addition to this study, we have conducted further work with
a wider community of health care professionals outside the
RADAR-CNS consortium in the form of an interview study to
gauge their views on the potential of RMT [33]. Whereas the
interviews in the study by Andrews et al [33] aimed to elicit the
types of data, specific time points, and job roles where RMT
data would be used, the use of UPOC in this study asked
participants to be more creative and imagine how particular
processes could be differently managed with the use of RMT.
Thus, responses in this study permitted capture of imagined
scenarios of use for RMT at specific points of care, for example,
how a change in treatment for MS might be enacted via a phone
call and the platform used to monitor the effect. The results here
are therefore more indicative of how clinical pathways might
change to accommodate the use of these technologies than in
the results of our previously published work, and the results of
this study incorporate both clinician and patient perspectives.
Limitations and Future Work
The results of this study are limited due to the population
sample, albeit by design, with its primary focus on health care
professionals and patient representatives from a research
consortium where one could presume most to be enthusiasts of
the technology being developed. In this study, the use of UPOC
has guided clinicians and patients to portray their own views
of how RMT should augment care. Within these portrayals,
participants were able to articulate where further inquiry was
necessary to achieve such improvements. Participants were of
the opinion that more research is needed to assess the sensitivity
and specificity of relapse prediction and that future prospective
trials should take place to assess the impact on clinical care and
patient outcomes. It is too early to say whether RMT could be
employed successfully in therapeutic trials or whether it can
really support individual disease management and stratification
of patients based on risk factors or treatment response.
Despite the benefits of our approach, responses in some areas
were not detailed enough to design a system based solely on
the outputs of this study. For example, it is not yet clear exactly
how the alerts and follow-up appointments that are triggered
by RMT will be managed in routine care, for example, would
they be directed first to patients, carers, or clinical services?
Would they generate automated (eg, programed behavioral
advice) or human responses? The survey did not reveal the
details of information that health care professionals require from
the system, for example, the required sensitivity and specificity
thresholds for alerts. However, it is clear that the UPOC method
was able to reveal the need to consider such details.
Beyond the scope of this study, the UPOC approach provides
learning for the design community, specifically those working
in the health and medical domains and in the development of
complex Information and Communication Technology
platforms. The approach taken to identify and design a
requirements capture exercise around UPOC has shown that
formative data capture is possible and will provide important
insights into how multifaceted platforms can meet the needs of
different stakeholders from different clinical specialties, for
whom there are different end goals.
Conclusions
The UPOC method employed in this study provided a targeted
and structured means by which to inquire about use of RMT in
real-world practice and bring clinical and patient opinion into
its design process. In addition, by adapting the model by
Sharples et al [7] to label solutions as enablers, enhancers,
facilitators, or catalysts, we were able to offer signposting to
technologists about how different aspects of the digital platform
could provide value in a number of different use case scenarios.
More generally, the UPOC approach provides a means to
explore the requirements of a complex technology system that
not only needs to meet the broad needs of traditional user
groups, such as health care professionals and patients, but also
has to accommodate the diverse experiences of those groups of
stakeholders from the range of clinical specialties within them.
A greater understanding of these needs will inform a meaningful
formative and summative evaluation of system design.
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